Trial Profile
Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Apr 2024
Price :
$35
*
At a glance
- Drugs TKD-activated natural killer cells (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 15 Apr 2024 Status changed from discontinued to completed.
- 01 Sep 2020 Status changed from suspended to discontinued.
- 01 Sep 2020 Results published in the Clinical Cancer Research